Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX001899 in KRAS G12C-mutant advanced solid tumors and non-small cell lung cancer
CTR20220611Phase 2Active
- Sponsor
- Shanghai Jiyu Medical Technology
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sosimerasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by Shanghai Jiyu Medical Technology. Started May 2022; status: active.
02
Drugs
sosimerasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220611.